慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展*

doi:10.3969/j.issn.1672-5069.2019.01.039

摘要/Abstract

摘要： 随着人们生活水平的改善,慢性乙型肝炎（CHB）合并非酒精性脂肪性肝病（NAFLD）的发病率持续升高。本文分析比较了CHB、NAFLD与CHB合并NAFLD患者在血清学指标、影像学和病理学检查方面存在的差异。由于病毒-宿主与代谢综合征等的关系仍备受争议,进而引发临床医生不同的治疗思路,这些都需要深入研究。

关键词: 慢性乙型肝炎, 非酒精性脂肪性肝病, 发病机制, 治疗

Abstract: The incidence rate of non-alcoholic fatty liver disease （NAFLD） with concurrent chronic hepatitis B （CHB） is increasing gradually. We will compare serum indexes, image and pathology characteristics among patients with NAFLD,CHB and NAFLD concurrent with CHB. The virus and host are both involved in the pathogenesis of steatosis. We will discuss all the above questions.

Key words: Chronic hepatitis B, Non-alcoholic fatty liver disease, Pathogenesis, Therapy

胡虎兰综述, 朱梦飞, 施军平审校. 慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展^*[J]. 实用肝脏病杂志, 2019, 22(1): 149-152.

Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.

参考文献

[1] European association for the study of the liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370.
[2] Abd ElKader SM,El Den Ashmawy EM. Non-alcoholic fatty liver disease:The diagnosis and management.World J Hepatol,2015,7(6):846.
[3] Wang MM,Wang GS,Shen F,et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci,2014,59(10):2571-2579.
[4] Liang J,Cai W,Han T,et al.The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.Medicine,2016,95(52):e5763.
[5] Machado M V,Oliveira A G,Cortez-Pinto H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol,2011,26(9):1361-1367.
[6] Liu X,Shen Z,Zhang H,et al.Interleukin-21 is associated with early antiviral response in patients with hepatitis B e antigen-positive chronic hepatitis B and nonalcoholic fatty liver disease. J Interferon Cytokine Res,2016,36(6):367.
[7] Yuki H,Haga YJ,Tatsuo S,et al.Nonalcoholic fatty liver disease and hepatic cirrhosis:comparison with viral hepatitis-associated steatosis. World J Gastroenterol,2015,21(46):12989.
[8] Chan A W,Wong G L,Chan H Y,et al.Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol,2017,32(3):667.
[9] Cheng Y L,Wang Y J,Kao W Y,et al.Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up. Plos One,2013,8(8):e72049.
[10] 施军平,范建高,武瑞, 等. 慢性乙型肝炎患者肝细胞脂肪变的发生率及其危险因素分析.中华肝脏病杂志,2008,16(7):519-523.
[11] 宓余强,刘勇钢,徐亮,等. 慢性乙型肝炎合并肝脂肪变的临床与病理学特征分析. 中华肝脏病杂志,2014,17(6):817-820.
[12] Nau AL,Soares JC,Shiozawa MB,et al.Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers. Rev Soc Bras De Med Trop,2014,47(2):158.
[13] Ceylan B,Arslan F,Batirel A,et al.Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol,2015,27(1):42.
[14] Zhu L Y,Wang Y G,Wei L Q,et al.The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. Drug De Devel Ther,2016,10:2739-2744.
[15] Chen J D.Sonographic fatty liver and hepatitis B virus carrier status:Synergistic effect on liver damage in Taiwanese adults. World J Gastroenterol,2007,13(12):1805.
[16] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病诊疗指南(2018年版). 实用肝脏病杂志. 2018,21(2):177-186.
[17] Weinstein A A,Kallman P J,Stepanova M,et al.Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics,2011,52(2):127-132.
[18] 中华医学会传染病与,寄生虫病学分会,肝病学分会. 病毒性肝炎防治方案. 中华内科杂志,2001,40(1):324-329.
[19] Yeom S K,Chang H L,Sang H C,et al.Prediction of liver cirrhosis,using diagnostic imaging tools. World J Hepatol,2015,7(17):2069.
[20] 贺文,马大庆,冯捷,等. CT定量诊断脂肪肝的临床研究. 中华放射学杂志,2001,35(11):829-831.
[21] Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int,2017,37 Suppl 1:85.
[22] Ballestri S,Nascimbeni F,Baldelli E,et al.Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism,2017,72:57-65.
[23] Hytiroglou P.17-Hepatitis B. Prac Hepatic Pathol,2011,33(6):215-224.
[24] Lefkowitch J H.Advances in hepatobiliary pathology:update for 2010.Clin Liver Dis,2010,14(4):747.
[25] Seto W K,Yuen M F.Nonalcoholic fatty liver disease in Asia:emerging perspectives. J Gastroenterol,2017,52(2):164.
[26] Wang CC,Kao JH.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease:a cohort study. Hepatology,2016,65(3):828.
[27] Nascimento A C,Maia D R,Neto S M,et al.Nonalcoholic fatty liver disease in chronic hepatitis B and C patients from western Amazon. Int J Hepatol,2012(4):695950.
[28] Negro F.Hepatitis C virus-induced steatosis:an overview. Dig Dis,2010,28(1):294.
[29] 江萃英,曾维琼,陈压西,等. 乙型肝炎病毒对肝脂肪变患者肝细胞固醇调节元件结合蛋白表达的影响.中华肝脏病杂志,2011,19(8):608-613.
[30] Kyeongjin K,Hwan K K,Jaehun C.Hepatitis B virus X protein impairs hepatic insulin signaling through degradation of IRS1 and induction of SOCS3. Plos One,2010,5(3):e8649.
[31] 陈娟,沈薇,程文会. 乙型肝炎病毒X蛋白对HepG2细胞脂代谢相关基因表达的影响. 中华肝脏病杂志,2011,19(10):768-773.
[32] Cheng Y L,Wang Y J,Kao W Y,et al.Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up. Plos One,2013,8(8):e72049.
[33] 施军平,范建高,武瑞,等. 慢性乙型肝炎患者肝细胞脂肪变的发生率及其危险因素分析. 中华肝脏病杂志,2008,16(7):519-523.
[34] Zheng R D,Chen J N,Zhuang Q Y,et al.Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci,2013,10(5):641-646.
[35] Zhang R N,Qin P,Zheng Z,et al.Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by Toll-Like receptor 4-Mediated innate immune response. Hepat Mon,2015,15(5):e27909.
[36] Pan Q,Zhang R N,Wang Y Q,et al.Linked PNPLA3 polymorphisms confer susceptibility tononalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J Gastroenterol,2015,21(28):8605-8614.
[37] 陆璐,柳银兰,杨文君,等. 慢性乙型肝炎病毒携带合并非酒精性脂肪性肝病小鼠模型建立与观察.中华实验和临床病毒学杂志,2013,27(5):332-335.
[38] Chen Y,Fan C,Chen Y,et al.Effect of hepatic steatosis on the progression of chronic hepatitis B:A prospective cohort and in vitro study. Oncotarget,2017,8(35):58601-58610.

慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展^*

Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[5]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[6]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[7]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[8]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[9]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[10]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[11]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[12]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[13]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[14]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[15]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.